Nobel Award Honors Pioneering Immune System Research

The Nobel Prize in medical science was awarded for revolutionary discoveries that clarify how the immune system targets harmful infections while sparing the healthy tissues.

Three esteemed scientists—Japan's Shimon Sakaguchi and American scientists Mary Brunkow and Fred Ramsdell—share this accolade.

Their research uncovered specialized "security guards" within the immune system that remove malfunctioning defense cells that could attacking the organism.

The discoveries are now paving the way for new treatments for immune disorders and cancer.

The laureates will divide a monetary award valued at 11 million SEK.

Decisive Findings

"Their work has been essential for understanding how the immune system functions and the reason we don't all suffer from severe autoimmune diseases," commented the head of the award panel.

This team's studies explain a core question: In what way does the immune system protect us from countless invaders while keeping our own tissues intact?

The immune system uses immune cells that search for indicators of disease, including pathogens and germs it has not met before.

These defenders utilize sensors—called receptors—that are generated randomly in countless combinations.

That provides the defense network the capacity to fight a wide array of invaders, but the unpredictability of the mechanism unavoidably creates immune cells that may target the body.

Security Guards of the Body

Researchers earlier understood that some of these problematic white blood cells were eliminated in the thymus—where white blood cells mature.

This year's Nobel Prize honors the identification of regulatory T-cells—described as the immune system's "security guards"—which travel through the body to neutralize other defenders that assault the healthy cells.

It is known that this mechanism malfunctions in self-attack conditions such as type-1 diabetes, multiple sclerosis, and RA.

A prize committee stated, "The discoveries have laid the foundation for a new field of research and spurred the creation of innovative therapies, for instance for cancer and immune disorders."

Regarding malignancies, regulatory T-cells block the body from fighting the tumor, so research are aimed at reducing their quantity.

For self-attack disorders, trials are testing boosting T-reg cells so the body is no longer under attack. A comparable method could also be useful in reducing the chances of transplanted organ rejection.

Innovative Studies

Professor Sakaguchi, from Osaka University, conducted tests on rodents that had their thymus removed, leading to autoimmune disease.

He showed that injecting immune cells from other mice could stop the disease—implying there was a mechanism for blocking immune cells from harming the body.

Dr. Brunkow, from the Institute for Systems Biology in Seattle, and Dr. Ramsdell, currently at a biotech firm in San Francisco, were studying an genetic immune disorder in rodents and humans that resulted in the identification of a genetic factor vital for how regulatory T-cells function.

"Their pioneering work has uncovered how the immune system is kept in check by T-reg cells, stopping it from accidentally attacking the healthy cells," said a prominent biological science specialist.

"This work is a striking example of how fundamental biological research can have far-reaching consequences for public health."